In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA_1c vs. daily basal insulin analogues at 52 wk

Aris Liakos,Thomas Karagiannis,Apostolos Tsapas

ANNALS OF INTERNAL MEDICINE（2024）

引用 0|浏览0

暂无评分

摘要

Source Citation Bajaj HS, Aberle J, Davies M, et al. Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5): a randomized trial. Ann Intern Med. 2023;176:1476-1485. 37748181 Clinical Impact Ratings GIM/FP/GP: Endocrinology:

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA1c vs. daily basal insulin analogues at 52 wk

In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA_1c vs. daily basal insulin analogues at 52 wk